6 Generic Products That Are Just As Good

AAA

Is Generic Just As Good?

Money-strapped shoppers are choosing generic over big name brands in their supermarket aisles. Consumers generally agree that generic diapers, toilet paper, condiments and cheese simply aren't worth the savings. However, there are a few generic products that make the grade. Here are 6 generics that are just as good as the real thing.

  1. No results found.
Related Articles
  1. Trading

    5 Generic Products That Are Just As Good

    While some generic products are second-rate, others are just as good as the real thing. Here are six generics that take the cake.
  2. Investing

    Market Vectors Launches First Generic Drugs ETF (GNRX)

    Generic drugs have been a growing market in recent years. Now there is an ETF targeted at this market.
  3. Investing

    Novartis Eyes $8B Buy of Generic Drug Firm (NVS)

    The potential $8 billion acquisition can help Novartis become the third-largest generic drug company in the US.
  4. Insurance

    How to Profit from the Generic Drug Trend

    Generic drugs are poised to steal market share as patent protections on a number of branded drugs expire. Investors should be ready, too.
  5. Investing

    FDA Rejects Mylan's Generic Version of Advair

    Glaxo is relieved after the FDA rejected rival Mylan's generic version of GSK's Advair.
  6. Investing

    Big Pharma Faces 'Pay For Delay' Lawsuits

    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of planning to lose nearly all revenue once the drug goes off patent, the ...
  7. Insights

    Why Are Prescription Drug Prices So High?

    Expensive drugs that don’t have affordable alternatives or generic equivalents are a serious concern today. So why are prescription drug prices so high?
  8. Insights

    Impax Hires Morgan Stanley for Strategic Review, Possible Sale

    The generic drug maker has hired Morgan Stanley to review available options, including an acquisition or sale of the company.
  9. Investing

    Cost of Old Cancer Drugs Rises in EU Amid Outcry

    The prices of several off-patent cancer drugs have soared more than 100% in Europe.
  10. Investing

    Endo Settles FTC 'Pay-for-Delay' Allegations

    Endo resolved a dispute with the FTC alleging that it paid rivals to delay generic drug rollouts.
Trading Center